These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16268451)

  • 1. [Adherence to treatment in osteoporosis influence on efficiency].
    Reginster JY; Rabenda V
    Rev Med Suisse; 2005 Oct; 1(35):2278-81. PubMed ID: 16268451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic adherence to bisphosphonates.
    Payer J; Killinger Z; Ivana Sulková ; Celec P
    Biomed Pharmacother; 2007 May; 61(4):191-3. PubMed ID: 17412550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compliance with treatment in osteoporosis patients--an ongoing problem.
    Sambrook P
    Aust Fam Physician; 2006 Mar; 35(3):135-7. PubMed ID: 16525527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
    Rabenda V; Hiligsmann M; Reginster JY
    Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.
    Payer J; Killinger Z; Sulková I; Celec P
    Biomed Pharmacother; 2008 Feb; 62(2):122-4. PubMed ID: 17888616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated approach: bisphosphonate management for the treatment of osteoporosis.
    Owens G; Jackson R; Lewiecki EM
    Am J Manag Care; 2007 Dec; 13 Suppl 11():S290-308; quiz S309-12. PubMed ID: 18095779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence and persistence: impact on outcomes and health care resources.
    Reginster JY
    Bone; 2006 Feb; 38(2 Suppl 2):S18-21. PubMed ID: 16443406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment].
    Bartl R; Götte S; Hadji P; Hammerschmidt T
    Dtsch Med Wochenschr; 2006 Jun; 131(22):1257-62. PubMed ID: 16755420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
    Zambon A; Baio G; Mazzaglia G; Merlino L; Corrao G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.
    van den Boogaard CH; Breekveldt-Postma NS; Borggreve SE; Goettsch WG; Herings RM
    Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.